Lupin appoints Abdelaziz Toumi as CEO of its API CDMO Subsidiary

Global pharma major Lupin Limited (Lupin) today announced the appointment of Abdelaziz Toumi (Abdel) as the Chief Executive Officer of its newly formed subsidiary, Lupin Manufacturing Solutions (LMS). LMS is engaged in the development, manufacture and sale of Active Pharmaceutical Ingredients and is starting to build its Contract Development and Manufacturing Operations (CDMO) business.

Abdel is a seasoned leader with a blend of scientific and commercial skills, and brings over two decades of rich experience in the biotech, pharma and CDMO sectors, spanning Europe, North America and Asia. He has held leadership positions at Bayer, Merck, Catalent, Lonza, and KBI Biopharma, where he was responsible for driving growth, innovation and operational excellence. Abdel will be based in Switzerland and will spend considerable time in India.

Abdel holds a Doctorate in Chemical Engineering and a Master's degree in Business Administration from the University of Southern Queensland.

Commenting on the appointment, Lupin's Managing Director, Nilesh Gupta said, "We are delighted to welcome Abdel to our team. He brings a wealth of knowledge and experience in the API CDMO space and will be instrumental in establishing LMS as a trusted and preferred partner for our global customers."

Shares of Lupin Limited was last trading in BSE at Rs. 1603.85 as compared to the previous close of Rs. 1605.35. The total number of shares traded during the day was 10734 in over 855 trades.

The stock hit an intraday high of Rs. 1624.00 and intraday low of 1597.80. The net turnover during the day was Rs. 17216443.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 Appointment CEO LupinManufacturingSolutions